Handbook of therapeutic antibodies

摘要: Volume I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future SELECTING AND SHAPING THE ANTIBODY MOLECULE Selection strategies Monoclonal II: Antibody Phage Display III: Transgenic Mice Bioinformatic Tools for Engineering Molecular Humanization Affinity Maturation Fc WAY INTO CLINIC Production and Downstream Processing Pharmaceutical Formulation Clinical Application Immunogenicity of Therapeutics Regulatory Considerations Intellectual Property Issues Emerging Developments BEYOND IGG: MODIFIED ANTIBODIES Immunoscintigraphy Radioimmunotherapy Bispecific Immunotoxins / Targeted RNases IV: EMERGING CONCEPTS Automation Alternative Systems Non-Antibody Scaffolds Concepts ADEPT Nanotechnology III:Cell-bound antibodies IV:Anti-idiotypic V: ONGOING CLINICAL STUDIES: in Phase I/II/III: Cancer Therapy Targeting TNF VOLUME APPROVED THERAPEUTICS Adalimumab (Humira) Alemtuzumab (Mabcampath) Bevacizumab (Avastin) Cetuximab (Erbitux) Efalizumab (Raptiva) Fanolesomab/Technetium99m (Neutrospec) Gemtuzumab Ozogamicin (Mylotarg) Infliximab (Remicade) Muromonab (Orthoclone) Natalizumab (Tysabri) Omalizumab (Xolair) Palivizumab (Synagis) Rituximab (Rituxan) Trastuzumab (Herceptin) Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab Votumumab